Increased level of heme oxygenase-1 in rheumatoid arthritis synovial fluid. 2011

Ai Kitamura, and Keiichiro Nishida, and Takamitsu Komiyama, and Hideyuki Doi, and Yasutaka Kadota, and Aki Yoshida, and Toshifumi Ozaki
Science of Functional Recovery and Reconstruction, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.

We investigated the expression and localization of heme oxygenase-1 (HO-1) in synovial fluid and synovial tissue, and examined the stimulation of HO-1 production in rheumatoid synovial fibroblasts (RASFs). Synovial fluid samples were obtained from knee joints of 20 rheumatoid arthritis (RA) and 20 osteoarthritis (OA) patients, and concentration of HO-1 and matrix metalloproteinase-3 (MMP-3) were measured by enzyme-linked immunosorbent assay (ELISA). Synovial tissues obtained from RA or OA patients during total knee arthroplasty (TKA) were used for immunohistochemical analysis of HO-1. HO-1 production by RASFs in response to various cytokines was examined by ELISA. HO-1 levels in synovial fluid were higher in the RA group than in the OA group with significant difference (P < 0.001), and correlated with serum C-reactive protein (CRP) level (r = 0.80, P < 0.01) in the RA group. Higher levels of HO-1 were seen in the RA-L group (Larsen grade III-V) than in the RA-E (Larsen grade 0-II) group (P < 0.001). There was weak correlation between the levels of HO-1 protein and MMP-3 in synovial fluid in the RA group (r = 0.31, P < 0.01), while no positive correlation was observed in OA. Positive immunoreaction for HO-1 was observed in cells of synovial tissue including synovial fibroblasts and cells in synovial pannus. HO-1 protein levels in cultured media of RASFs were increased by stimulation by interleukin-1β at 6 h and tumor necrosis factor-alpha at 12 h, but suppressed by interferon-gamma at 12 and 24 h. These results indicated that HO-1 expression in synovial tissue might be stimulated by inflammatory cytokines. The correlation of HO-1 concentration in synovial fluid with serum CRP and MMP-3 in joint fluid indicated that HO-1 might be useful as a marker of joint inflammation in RA patients.

UI MeSH Term Description Entries
D008070 Lipopolysaccharides Lipid-containing polysaccharides which are endotoxins and important group-specific antigens. They are often derived from the cell wall of gram-negative bacteria and induce immunoglobulin secretion. The lipopolysaccharide molecule consists of three parts: LIPID A, core polysaccharide, and O-specific chains (O ANTIGENS). When derived from Escherichia coli, lipopolysaccharides serve as polyclonal B-cell mitogens commonly used in laboratory immunology. (From Dorland, 28th ed) Lipopolysaccharide,Lipoglycans
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D005260 Female Females
D005347 Fibroblasts Connective tissue cells which secrete an extracellular matrix rich in collagen and other macromolecules. Fibroblast
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old

Related Publications

Ai Kitamura, and Keiichiro Nishida, and Takamitsu Komiyama, and Hideyuki Doi, and Yasutaka Kadota, and Aki Yoshida, and Toshifumi Ozaki
April 2006, Arthritis and rheumatism,
Ai Kitamura, and Keiichiro Nishida, and Takamitsu Komiyama, and Hideyuki Doi, and Yasutaka Kadota, and Aki Yoshida, and Toshifumi Ozaki
September 1980, British medical journal,
Ai Kitamura, and Keiichiro Nishida, and Takamitsu Komiyama, and Hideyuki Doi, and Yasutaka Kadota, and Aki Yoshida, and Toshifumi Ozaki
March 2004, Autoimmunity reviews,
Ai Kitamura, and Keiichiro Nishida, and Takamitsu Komiyama, and Hideyuki Doi, and Yasutaka Kadota, and Aki Yoshida, and Toshifumi Ozaki
January 1980, Scandinavian journal of rheumatology,
Ai Kitamura, and Keiichiro Nishida, and Takamitsu Komiyama, and Hideyuki Doi, and Yasutaka Kadota, and Aki Yoshida, and Toshifumi Ozaki
December 1958, Arthritis and rheumatism,
Ai Kitamura, and Keiichiro Nishida, and Takamitsu Komiyama, and Hideyuki Doi, and Yasutaka Kadota, and Aki Yoshida, and Toshifumi Ozaki
January 2016, Clinical proteomics,
Ai Kitamura, and Keiichiro Nishida, and Takamitsu Komiyama, and Hideyuki Doi, and Yasutaka Kadota, and Aki Yoshida, and Toshifumi Ozaki
January 2010, Clinical and experimental rheumatology,
Ai Kitamura, and Keiichiro Nishida, and Takamitsu Komiyama, and Hideyuki Doi, and Yasutaka Kadota, and Aki Yoshida, and Toshifumi Ozaki
April 1986, Arthritis and rheumatism,
Ai Kitamura, and Keiichiro Nishida, and Takamitsu Komiyama, and Hideyuki Doi, and Yasutaka Kadota, and Aki Yoshida, and Toshifumi Ozaki
February 1967, American journal of clinical pathology,
Ai Kitamura, and Keiichiro Nishida, and Takamitsu Komiyama, and Hideyuki Doi, and Yasutaka Kadota, and Aki Yoshida, and Toshifumi Ozaki
May 1989, The Journal of rheumatology,
Copied contents to your clipboard!